Results 21 to 30 of about 13,727 (197)

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]

, 2016
BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C., Baxter, A., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., Dayanandan, R., Emberson, J., Haynes, R., Herrington, W.G., Hill, M., Judge, P.K., Kalra, P.A., Knott, C., Landray, M.J., McMurray, John J., Murphy, K., Roderick, P., Staplin, N., Storey, B.C., Taal, M., Tomson, C., Wheatley, K., Wheeler, D.C.   +23 more
core   +4 more sources

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2018
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham, Andersen, Anker, Anker, Borer, Ghosh, Greenberg, Lin, McMurray, McMurray, Metcalfe, Neaton, Packer, Rogers, Rogers, Rogers, Rogers, Solomon, Wei   +18 more
core   +3 more sources

Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]

, 2016
Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L., Desai, Akshay S., Lefkowitz, Martin, McMurray, John J.V., Packer, Milton, Rouleau, Jean L., Shi, Victor, Solomon, Scott D., Starling, Randall, Swedberg, Karl, Teerlink, John, Zile, Michael R.   +11 more
core   +2 more sources

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]

, 2017
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Böhm, Michael, Gong, Jianjian, Jhund, Pardeep, Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Young, Robin, Zile, Michael R.   +12 more
core   +1 more source

Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats

Renal Failure, 2021
Salt-sensitive (SS) hypertension is accompanied with severe cardiorenal complications. In this condition, elevated blood pressure (BP) resulting from salt retention is associated with counterintuitively lower levels of atrial natriuretic peptide (ANP ...
Iuliia Polina, Morgan J. Spicer, Mark Domondon, Ryan S. Schibalski, Elizaveta Sarsenova, Regina F. Sultanova, Daria V. Ilatovskaya   +6 more
doaj   +1 more source

Potential of valsartan+sacubitril therapy in hypertensive heart disease

Российский кардиологический журнал, 2021
The course of hypertension is often complicated by left ventricular hypertrophy (or hypertensive heart disease, HHD). The main “corridor” of natural HHD is development of heart failure with preserved ejection fraction (HFpEF).
A. G. Ovchinnikov, A. D. Gvozdeva, A. V. Potekhina, M. V. Vitsenya, F. T. Ageev   +4 more
doaj   +1 more source

Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel

Frontiers in Cell and Developmental Biology, 2021
Heart failure caused by cardiac fibrosis has become a major challenge of public health worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are crucial pathological features, both of which are associated with aberrant Ca2 ...
Tian Jia, Xiaozhi Wang, Yiqun Tang, Wenying Yu, Chenhui Li, Shufang Cui, Juanjuan Zhu, Wei Meng, Chen Wang, Quanyi Wang   +9 more
doaj   +1 more source

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift

South African Family Practice, 2016
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care.
M. O.E. Irhuma, M. Vally
doaj   +1 more source

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats

Molecules, 2021
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties.
Pema Raj, Karen Sayfee, Mihir Parikh, Liping Yu, Jeffrey Wigle, Thomas Netticadan, Shelley Zieroth   +6 more
doaj   +1 more source